Idorsia Ltd. · SIX:IDIA
Idorsia — H1 2024 Earnings Presentation
13 slides from Idorsia's earnings presentation, Jul 25, 2024
Slide 1: Half Year 2024 Financial Reporting
Financial 20 Reporting HALF YEAR 24 Investor webcast – July 2024
Slide 2: Forward-looking statements
The following information contains certain “forward-looking statements”, relating to the company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”,
Slide 3: Highlights of H1 2024
Viatris collaboration Approval of for selatogrel and aprocitentan cenerimod TRYVIO in the US JERAYGO in the EU Restructured QUVIVIQ NDA convertible bond – submitted in extending cash Greater China by runway Simcere Highlights of Adapted governance Vaccine for structure H1 2024 Clostridium Difficile
Slide 4: What needs to be done in H2 2024
Extend the cash runway Continue to increase sales of QUVIVIQ What needs to be done in H2 2024 Prepare for the launch Continue to innovate of TRYVIO in the US 4 HY 2024 Financial Reporting | 25 Jul 2024
Slide 5: US sales outpaces field force changes
US sales outpaces field force changes US net sales QUVIVIQ field force 9.4 349 CHF million 328 7.7 283 260 6.2 6.5 5.8 222 3.0 100 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Daridorexant is available in the US, Germany, Italy, Spain, Switzerland,
Slide 6: TRYVIO US launch on track
TRYVIO US launch on track 2024 2025 Q3 Q4 Q1 Commercial Supply REMS program Distribution Network MSLs Congress presence AHA-HTN ASN AHA Sales Reps Payer discussions Rolling discussions Aprocitentan is only approved in the US under the tradename TRYVIO where it will be made available later in 2024, a
Slide 7: EUCAN net sales growth
EUCAN net sales growth 6.0 CHF million 3.5 2.2 AMNOG 1 1.6 1.3 1.3 1.0 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Daridorexant is available in the US, Germany, Italy, Spain, Switzerland, the UK, Canada, Austria, and France under the tradename QUVIVIQ. In addition, daridorexant is approv
Slide 8: EUCAN reimbursement status
EUCAN reimbursement status 2024 2025 Current status H2 H1 H2 Germany Reimbursed AMNOG 2 Reimbursement Price UK Reimbursed France Reimbursed Private Canada access Reimbursement discussions Switzerland OOP Reimbursement discussions Italy OOP Reimbursement discussions Austria OOP Reimbursement discussi
Slide 9: Non-GAAP operating results
Non-GAAP operating results HY 2023 as reported in CHF millions, rounding differences may occur HY 2023 proforma1 HY 2024 as reported 51 19 26 0 0 3 -5 -2 -4 -61 -153 -146 -134 -170 -235 -216 -342 -346 Net revenue Cost of sales R&D SG&A Other income Non-GAAP operating results 1 excluding the business
Slide 10: HY 2024 vs 2023 operating performance
HY 2024 vs 2023 operating performance HY 2024 performance as reported HY 2023 performance proforma1 CHF million Idorsia Partnered Global Idorsia Partnered Global business business Business business business Business REVENUE 24 3 26 12 6 19 COGS -4 – -4 -2 – -2 SG&A OPEX -134 – -134 -216 – -216 R&D O
Slide 11: HY 2024 cash development
HY 2024 cash development in CHF millions, rounding differences may occur 308 237 -36 24 145 -134 -61 -8 Liquidity Product SG&A R&D Other Upfront R&D Liquidity Jan 1, 2024 sales OPEX OPEX Viatris Deal contribution Jun 30, 2024 Viatris Deal 11 HY 2024 Financial Reporting | 25 Jul 2024
Slide 12: Financial outlook
Financial outlook Guidance for 2024 CHF million Idorsia Partnered Global business business Business REVENUE 55 15 70 COGS -10 -10 -20 SG&A OPEX -300 – -300 R&D OPEX -145 0 -145 Non-GAAP EBIT -400 5 -395 D&A -15 – -15 SBC -35 – -35 Other – 125 125 US-GAAP EBIT -450 130 -320 Excluding unforeseen event
Slide 13: More questions?
More questions? 13 HY 2024 Financial Reporting | 25 Jul 2024